To that end, Jianhua Mao conducted a study to evaluate how EGFR L858R/T790M mutation can be targeted and degraded by As2O3 treatment using three NSCLC (NCI-H1975, HCC827, and A549) cell lines. Here, EGFR is linked to non-small cell lung carcinoma.